The share price of Shattuck Labs, Inc. (NASDAQ: STTK) saw a little gain on Thursday during the extended trading session. STTK shares decreased 9.26% to $4.16 at the close of the regular session, but then increased 5.64% to $4.40 in the after-market trading. Even though there were no noteworthy fresh events, the market's better attitude seemed to be the driving force behind the stock price's recent surge.
- Updated Clinical Trial Data
- Encouraging Results And Future Plans
Updated Clinical Trial Data
Shattuck Labs (STTK) last week announced a preliminary result from the Phase 1B dose expansion clinical study of SL-172154 with azacitidine for frontline HR-MDS and TP53-mutant AML patients. On June 14, 2024, Shattuck gave a poster session presentation of his findings at the European Hematology Association (EHA) 2024 Congress. The information emphasized SL-172154's distinct mode of action and confirmed its status as a top CD47 inhibitor in hematologic malignancies.
Encouraging Results And Future Plans
The latest data reveal an improvement in the complete remission rate since the previous update in December, with additional patients in both cohorts showing continued progress. Due to these promising results, Shattuck Labs is concentrating its efforts on HR-MDS and TP53-mutated AML, areas with significant unmet needs, minimal competition, and potential for expedited approval pathways.
The accumulating evidence highlights the therapeutic potential and manageable safety profile of SL-172154 for patients with previously untreated HR-MDS and TP53-mutated AML. Clinical evidence suggests a pharmacodynamic effect of CD40 activation in the peripheral blood and a developing correlation between clinical remission and CD40-mediated cytokine induction.
Patients treated by Shattuck Labs represent a high-risk group with historically short durations of complete remission and overall survival when treated with azacitidine alone. The median overall survival and duration of remission have not yet been reached.
Shattuck Labs plans to share additional data on treatment durability later this year and is actively enrolling patients in the randomized, controlled expansion cohort for frontline HR-MDS. The company anticipates regulatory discussions later this year to define the registration strategy for SL-172154.
週四在延長交易時段中，Shattuck Labs公司 (納斯達克: STTK) 股票價格有所上漲。在常規交易結束時，STTK股票價格跌了9.26％，至4.16美元，但在盤後交易中漲了5.64％，至4.40美元。儘管沒有什麼值得注意的新鮮事，但市場的良好態度似乎是股票價格最近上漲的推動力。
更新的臨床試驗數據
Shattuck Labs (STTK) 上週公佈了SL-172154與前線高風險腫瘤綜合徵（HR-MDS）和TP53突變AML患者使用阿扎胞苷的1B劑量擴大臨床研究的初步結果。2024年6月14日，Shattuck在歐洲血液學協會（EHA）2024年會議上展示了他的研究成果。該信息強調了SL-172154的獨特作用方式，並確認其作爲血液學惡性腫瘤領域頂尖的CD47抑制劑的地位。
鼓舞人心的結果和未來計劃
最新數據顯示，與去年12月的更新相比，完全緩解率有所提高，兩個隊列中的患者顯示出持續的進展。由於這些有希望的結果，Shattuck Labs將其力量集中在HR-MDS和TP53突變AML等零售銷售點，這些領域有着巨大的未滿足需求，很少有競爭，具有加速批准途徑的潛力。
積累的證據突出了SL-172154對先前未治療的HR-MDS和TP53突變AML患者的治療潛力和可管理的安全性。臨床證據表明，CD40激活在外周血液中產生藥效作用，並在CD40介導的細胞因子誘導和臨床緩解之間產生了關聯。
由Shattuck Labs治療的患者代表了一個高風險股票群體，當單獨使用阿扎胞苷治療時，緩解期的中位數和總生存期尚未達到。
Shattuck Labs計劃在今年晚些時候共享更多關於治療持久性的數據，並積極招募前線HR-MDS的隨機對照擴展隊列中的患者。該公司預計在今年晚些時候進行監管討論，以定義SL-172154的註冊策略。
